Maximum Tolerated Dose (MTD) of Liposomal Doxorubicin in Combination With Seliciclib for Patients With Metastatic Triple Negative Breast Cancer (TNBC)
Status: WITHDRAWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Liposomal Doxorubicin|DRUG: Seliciclib
Sponsor: M.D. Anderson Cancer Center
Collaborators: National Institutes of Health (NIH)